Pfizer to develop mRNA vaccines without BioNTech

The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines.

| More on:
asx share associated with COVID vaccine represented by lab tech drawing down syringe

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Pfizer Inc (NYSE: PFE)'s success in developing an effective COVID-19 vaccine in record time has given the pharmaceutical giant the confidence to invest heavily in the technology that underpins that vaccine. In an interview with The Wall Street Journal on Tuesday, CEO Albert Bourla revealed that Pfizer plans to become a leader in the development of new vaccines that rely on messenger RNA (mRNA).

Unfortunately for BioNTech (NASDAQ: BNTX), those plans don't rely on a continuation of the collaboration agreement that brought the world its first authorized mRNA-based vaccine. According to Bourla, Pfizer doesn't need to work with BioNTech anymore because it has the expertise to develop those new vaccines on its own.

Pfizer still has options to license two more BioNTech vaccines, one directed against cytomegalovirus (CMV) and another meant to prevent respiratory syncytial virus (RSV). Despite a great deal of effort over the past 50 years, there still aren't any effective vaccines approved to protect against those viruses. 

If Pfizer can rapidly develop new mRNA vaccines as Bourla suggests, it's easy to see why the company would rather strike out on its own. Pfizer and BioNTech are splitting the profits on BNT162b2 evenly at the moment. It's hard to say how much will hit their bottom lines, but the partners expect sales of the COVID-19 vaccine to reach around $15 billion this year.

If it turns out that annual booster shots are not needed, coronavirus vaccine sales could taper off significantly before the end of 2022, then dwindle to nearly nothing by 2024. BioNTech will have plenty of cash to fund the development of new mRNA drugs on its own, but competing with Pfizer will be a challenge. Bourla also said Pfizer intends to apply recently learned lessons to develop new mRNA vaccines at a blistering pace in the future.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Digital rocket on a laptop.
Broker Notes

Is the Nvidia share price on course to reach US$1,400?

You betcha, says one analyst.

Read more »

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Could Nvidia become the most valuable stock on earth?

Can anything stop the Nvidia stock price?

Read more »

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
International Stock News

What can ASX investors learn from Warren Buffett's latest buys and sells?

We've just found out what Buffett's been buying and selling recently.

Read more »

electric vehicle such as Tesla being charged at charging station
International Stock News

Why Tesla stock tanked in January

Will the electric vehicle leader see earnings decline once again in 2024?

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

Will Nvidia stock be worth more than Microsoft by 2030?

The graphics giant has been growing at a much faster pace than Microsoft, but can it sustain that momentum?

Read more »

Man with hands in the middle of two items with money bags on them.
International Stock News

Stock-split watch: Is Tesla next?

Stock splits are fun. But how much substance there is in Tesla splitting its stock is debatable.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
International Stock News

Yes, Microsoft is a star AI stock, but this is what really powered its solid second-quarter results

Deep involvement with artificial intelligence (AI) has made the company popular with investors, but that isn't (yet) the top motor…

Read more »

Search toolbar with a finger pointing to it.
International Stock News

Why Alphabet stock was sliding today

Shares of the tech giant pulled back on weaker-than-expected ad revenue in its fourth-quarter report.

Read more »